Dose escalation: what to expect

Overview

Every GLP-1 medicine starts at a dose too low to produce much weight loss. That is deliberate. The starting dose exists to let your gut adapt, not to shift weight.

Why slow escalation matters

Nausea, reflux and constipation are dose-related. Going up too quickly is the commonest reason people abandon treatment in the first two months, and — if it causes vomiting or poor fluid intake — the commonest reason kidney function drops.

The licensed schedules step up roughly every four weeks:

• Semaglutide (Wegovy): 0.25 mg weekly, then 0.5 mg, 1 mg, 1.7 mg and 2.4 mg, each for about four weeks before the next step.
• Tirzepatide (Mounjaro): 2.5 mg weekly for four weeks, then 5 mg, with further increases in 2.5 mg steps to a maximum of 15 mg, each step held for at least four weeks.

Your clinician may hold a dose for longer, or stop escalating altogether. A dose that is working with tolerable side effects is the right dose — there is no prize for reaching the maximum.

What each stage tends to feel like

• Weeks 1-4. Appetite change is often modest. Mild nausea for a day or two after each injection is typical. Weight change may be small.
• Weeks 5-12. Most people notice the clear appetite effect. This is the stage where portions need to be rebuilt around protein and fluid, not just made smaller.
• Weeks 12-24. Steady loss of roughly 0.5-1% of body weight a week is a good pace. Faster is usually fluid, muscle, or both.
• Beyond 6 months. Loss slows and plateaus are normal. The 26-week review looks at whether the medicine is still earning its place.

When to hold or step back down

Tell the clinic before the next increase if you have:

• nausea or vomiting that has not settled after two weeks;
• constipation that laxatives are not controlling;
• dizziness on standing, dark urine, or a day of poor fluid intake;
• unintended weight loss faster than about 1 kg a week;
• any change in your dialysis session tolerance or in your usual blood results.

Holding at the current dose for another four weeks, or dropping back one step, is a normal clinical decision — not a failure.

Missed and late doses

If you remember a missed weekly dose within a few days, take it and continue as normal. If your next scheduled dose is very close, skip the missed one — never double up. If more than a couple of weeks have passed, contact the clinic: you may need to restart at a lower dose and escalate again.

How this clinic handles dose changes

Every dose change is recorded on your monitoring record with the date it changed and who prescribed it, so your dose history is auditable at each review. Your weekly weight sits alongside it, which is what allows a six-weekly review to be a real clinical judgement rather than a guess.

When to contact your care team

Contact the clinic promptly if you have any of the following:

• Vomiting or diarrhoea lasting more than 24 hours, or you cannot keep fluids down
• Passing much less urine than usual, or new swelling of the legs or face
• Severe pain in the upper abdomen that spreads to your back, with or without vomiting
• A weight change of more than 2 kg in a week that is not explained by fluid
• A missed weekly weight, a missed dose, or any hospital admission

If you are seriously unwell, contact NHS 111 or your renal unit directly rather than waiting for your next review.

References

• NICE TA875 — Semaglutide for managing overweight and obesity
• NICE TA1026 — Tirzepatide for managing overweight and obesity
• NHS — Semaglutide (including Wegovy)
• NHS — Tirzepatide (Mounjaro)
• NICE NG203 — Chronic kidney disease: assessment and management

This page is general information, medically reviewed for accuracy. Always follow the dose instructions given to you personally.